Traduction de «relative risk ou risk » (Français → Néerlandais) :

- RR: relative risk ou risk ratio
- RR: relative risk or risk ratio

Du RHM (2008): fichier ‘données relatives au patient’: champ 5: année de naissance; fichier ‘données relatives au séjour’: champ 17: sexe, champ 22: code statut en matière d’assurance, champ 23: lieu avant l’admission, champ 24: type d’admission, champ 25: renvoi par, champ 26: destination, champ 27: type de sortie; numéro d’agréation de l’hôpital, année d’enregistrement, période d’enregistrement, numéro de séjour, variable dérivée APR-DRG 15.0, variable dérivée Risk of mortality, variable dérivée Severity of illness; fichier ‘données relatives au séjour’: champ 29: diagnostic d’admission vérifié, fichier ‘données relatives au diagnostic’, champ 6: code diagnostic principal / secondaire, champ 8: code diagnostic, champ 9: présent lors de l’admission.
Uit de MZG (2008): Bestand ‘gegevens over de patiënt’: Veld 5: geboortejaar; Bestand ‘gegevens over het verblijf’: Veld 17: geslacht, Veld 22: code verzekeringsstatus, Veld 23: plaats voor opname, Veld 24: type opname; Veld 25: verwezen door, Veld 26: bestemming, Veld 27: type ontslag; Erkenningsnummer van het ziekenhuis, Registratiejaar, Registratieperiode, Verblijfsnummer, Afgeleide variabele APR-DRG 15.0, Afgeleide variabele Risk of mortality, Afgeleide variabele Severity of illness; Bestand ‘gegevens over het verblijf’: Veld 29: geverifieerde opnamediagnose, Bestand ‘gegevens over de diagnoses’, Veld 6: code hoofd- / nevendiagnoses, Veld 8: code diagnose, Veld 9: aanwezig bij opname.

Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

In the reviews of CEA, it is shown that the posterior risk tends to be more constant, not the relative risk (the posterior risk divided by the prior risk) (see figure 4 in cited reference) 23 .
In the reviews of CEA, it is shown that the posterior risk tends to be more constant, not the relative risk (the posterior risk divided by the prior risk) (see figure 4 in cited reference)23.

oral glucose tolerance test Office de la Naissance et de l'Enfance odds ratio over-the-counter papanicolou plasma protein A polymerase chain reaction Public Health Laboratory Service pregnancy-induced hypertension proton pump inhibitor positive predictive value premature rupture of membranes routine antenatal anti-D prophylaxis Royal College of Obstetricians and Gynaecologists randomised controlled trial eferences rhesus D recombinant immunoblot assay Rijksinstituut voor Ziekte- en Invaliditeitsverzekering ribonucleic acid random plasma glucose rapid plasmin reagin test relative risk reagent strip testing standard deviation single entry two step symphysis-fundal height small for gestational age Scottish Intercollegiate Guidelines Network sexueel overdraagbare aandoening Society of Obstetricians and Gynaecologists of Canada symphysis pubis dysfunction Treponema pallidum haemagglutination assay thyroïd stimulating hormone nconjugated oestriol United Kingdom United States Centers for Disease Control and Prevention US Preventive Services Task Force ultrasound scan urinary tract infection Veneral Disease Research Laboratory (test for syphilis) vaginal examination Vlaamse Organisaties van Vroedvrouwen Vlaamse Vereniging voor Obstetrie en Gynaecologie Wereldgezondheidsorganisatie World Health Organization weighted mean difference Wetenschappelijke Vereniging van Vlaamse Huisartsen
Office de la Naissance et de l'Enfance odds ratio over-the-counter papanicolou plasma protein A polymerase chain reaction Public Health Laboratory Service pregnancy-induced hypertension proton pump inhibitor positive predictive value premature rupture of membranes routine antenatal anti-D prophylaxis Royal College of Obstetricians and Gynaecologists randomised controlled trial eferences rhesus D recombinant immunoblot assay Rijksinstituut voor Ziekte- en Invaliditeitsverzekering ribonucleic acid random plasma glucose rapid plasmin reagin test relative risk reagent strip testing standard deviation single entry two step symphysis-fundal height small for gestational age Scottish Intercollegiate Guidelines Network sexueel overdraagbare aandoening Society of Obstetricians and Gynaecologists of Canada symphysis pubis dysfunction Treponema pallidum haemagglutination assay thyroïd stimulating hormone nconjugated oestriol United Kingdom United States Centers for Disease Control and

ERR: excess relative risk/ excès de risque relatif.
ERR: excess relative risk/ toegevoegd relatief risico.

Remerciements : Pour son aide précieuse relative à la méta-analyse : Cécile Dubois (KCE) Pour leur contribution au scoring des indicateurs : Raf Brouns et Matthieu Rutgers (Belgian Stroke Council) Pour la validation de la description de leur pays : Suède : Kiell Asplund (Chair, Risks Stroke Umea), Bo Norrving (Professor, Lund University-Steering committee member Riks stroke) Pays-Bas : Martien Limburg (Neuroloog, Flevoziekenhuis, Almere, Stichting Kennisnetwerk) Ecosse : Martin Dennis (Division of Clinical Neurosciences – Western General Hospital University of Edinburgh), Peter Langhorne (Professor of Stroke Care, Cardiovascular and Medical Sciences Division – University of Glasgow) Grande-Bretagne : Patrick Gompertz (Barts and the London Brain Attack Center, London), Gill Gluckie (Clinical lead, stroke, Guy’s and St. Thomas’ hospital, clinical lead, S/East London stroke network) France : France Woimant (Service de neurologie, hôpital Lariboisière, Paris – “Agence Régionale de Santé – Ilede-France”), Didier Leys (Département de neurologie, Hôpital universitaire de Lille) Allemagne : Peter Heuschmann (Neurologische klinik und poliklinik, Universitätsklinikum Würzburg) German Stroke Register Study Group), E. Bernd Ringelstein (Neurologische klinik und poliklinik, Universitätsklinikum Münster)
Acknowledgements: Voor haar waardevolle bijdrage in het gedeelte over meta-analyse: Cécile Dubois (KCE) Voor hun bijdrage bij het scoren van de indicatoren: Raf Brouns en Matthieu Rutgers (Belgian Stroke Council) Voor het valideren van de informatie over hun land: Zweden: Kiell Asplund (Chair, Risks Stroke Umeal), Bo Norrving (Professor, Lund University-Steering committee member Riks stroke) Nederland: Martien Limburg (Neuroloog, Flevoziekenhuis, Almere, Stichting Kennisnetwerk); Schotland: Martin Dennis (Division of Clinical Neurosciences – Western General Hospital University of Edinburgh), Peter Langhorne (Professor of Stroke Care, Cardiovascular and Medical Sciences Division – University of Glasgow) Verenigd Koninkrijk: Patrick Gompertz (Barts and the London Brain Attack Center, London), Gill Gluckie (Clinical lead, stroke, Guy’s and St. Thomas’ hospital, clinical lead, S/East London stroke network) Frankrijk: France Woimant (Service de neurologie, hôpital Lariboisière, Paris – “Agence Régionale de Santé – Ile-de-France”), Didier Leys (Département de neurologie, Hôpital universitaire de Lille) Duitsland: Peter Heuschmann (Neurologische klinik und poliklinik, Universitätsklinikum Würzburg) German Stroke Register Study Group), E. Bernd Ringelstein (Neurologische klinik und poliklinik, Universitätsklinikum Münster)

In this chapter, we highlighted the indicators for which we observed a relative risk (RR) as large as 1.2 (or 0.83 when the gradient was reverse). Limitations The inequalities could not be measured for all the indicators due to lack of data on social position.
Limitations The inequalities could not be measured for all the indicators due to lack of data on social position.